UBS Group
MBVX

UBS Group’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

UBS Group’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11,889
Closed -$10K – 8600
2018
Q2 		$10K Buy
11,889
+10,237
+620% +$13K ﹤0.01% 7172
2018
Q1 		$2K Sell
1,652
-4,197
-72% -$9.07K ﹤0.01% 7601
2017
Q4 		$12K Sell
5,849
-4,359
-43% -$9.64K ﹤0.01% 6936
2017
Q3 		$20K Buy
10,208
+8,493
+495% +$18.6K ﹤0.01% 6470
2017
Q2 		$7K Buy
1,715
+63
+4% +$339 ﹤0.01% 7011
2017
Q1 		$11K Buy
+1,652
New +$14.3K ﹤0.01% 6583
2016
Q4 		– Sell
-45
Closed -$1K – 8270
2016
Q3 		$1K Buy
+45
New +$678 ﹤0.01% 7577

Other funds holding MBVX

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

UBS Group's MBVX Position: Q3 2018 in Review

UBS Group sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2018, closing a stake of 11,889 shares — an estimated $10K sold.

UBS Group first reported a position in MBVX in Q3 2016 and held it in 7 quarters. The position peaked at $20K in Q3 2017. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

  • UBS Group reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2018 after selling out during the quarter.
  • UBS Group sold 11,889 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2018, an estimated $10K.
  • UBS Group first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2016 and held it in 7 quarters.
  • UBS Group's MABVAX THERAPEUTICS HLDGS INC position peaked at $20K in Q3 2017.
  • 2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.